Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JNJ-63733657 in Participants with Early Alzheimer's Disease
2020-000116-30Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing JNJ-63733657 with Placebo (2 arms). Primary endpoint: Primary: Change from baseline on the iADRS. Started Dec 2020; status: active.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-000116-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000116-30.